-
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed'
Thursday, June 1, 2023 - 2:13pm | 978One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug Company, which announced a new initiative Thursday. What Happened: Cuban launched the Mark Cuban Cost...
-
3 Stocks At An Inflection Point
Friday, February 17, 2023 - 11:42am | 770With consumer and producer prices surprising to the upside, multiple research outlets are starting to call for more aggressive Fed against. We talk about the implications of higher than expected producer and consumer prices this week and what it means for monetary policy going forward. We also...
-
FDA Accepts Coherus Biosciences' Adalimumab Biosimilar Application For Review
Wednesday, February 17, 2021 - 11:00am | 213The FDA has accepted for review Coherus BioSciences Inc's (NASDAQ: CHRS) marketing application for CHS-1420 and AbbVie's Inc (NYSE: ABBV) Humira (adalimumab) biosimilar product candidate, with action for December 2021. If approved, Coherus plans to launch...
-
Abbott CEO Miles White Steps Down
Wednesday, November 13, 2019 - 12:23pm | 421After nearly 21 years at Abbott Laboratories (NYSE: ABT), CEO Miles White is preparing for his departure. The company announced Wednesday that White will leave March 31 and be replaced by Robert Ford, Abbott's current president and COO. White will leave a stark print on his longtime corporate...
-
Analysts Cut AbbVie Price Targets After Earnings Miss
Monday, January 28, 2019 - 11:59am | 504AbbVie Inc (NYSE: ABBV) dropped Friday after falling short of fourth-quarter earnings estimates. A $1.90 bottom line missed a $1.93 estimate, and sales of $8.305 billion underperformed forecasts of $8.37 billion. The Analysts Morgan Stanley analyst David Risinger maintained an Equal-weight rating...
-
AbbVie's Stock Hit By Citron Tweet
Thursday, July 19, 2018 - 11:58am | 589In a speech on Wednesday, U.S. Food and Drug Administration commissioner Scott Gottlieb ripped drug makers for blocking competitors from bringing potentially cheaper biosimilar drugs to the market. On Thursday, Citron Research, which is known for its short theses, tweeted that Gottlieb’s...
-
Leerink Upgrades Mylan On Barrage Of Catalysts, Diversified Platforms
Thursday, April 12, 2018 - 12:26pm | 390Mylan NV (NASDAQ: MYL)’s had a rough three years, but one analyst left the pharma company's investor day with fresh optimism. The Rating Leerink analyst Ami Fadia upgraded Mylan from Market Perform to Outperform and maintained a $52 price target. The Thesis By Leerink’s...
-
AbbVie Shares Double In A Year; Leerink Moves To Sidelines
Monday, January 29, 2018 - 4:51pm | 487AbbVie Inc (NYSE: ABBV) shares ran up about 14 percent last Friday following the release of fiscal fourth-quarter results, where it revealed expectations for higher earnings and a lower tax rate in 2018. The Analyst Leerink analyst Geoffrey Porges downgraded shares of AbbVie from...
-
Plenty Of Opportunity In AbbVie, Even After Recent Run
Monday, October 2, 2017 - 12:18pm | 345Analysts at Leerink Swann turned bullish on AbbVie Inc (NYSE: ABBV) and sees continued upside to the stock on top of the 43 percent gain since the start of 2017. The firm's Geoffrey Porges upgraded AbbVie's stock rating from Market Perform to Outperform with a new $106 price target. The bullish...
-
UBS Downgrades AbbVie; Here's What Changed Analysts' View
Monday, September 25, 2017 - 9:29am | 537UBS downgraded shares of AbbVie Inc (NYSE: ABBV), citing valuation and a likely delay in the U.S. biosimilar competition for Humira. Humira is AbbVie's best-selling drug approved to treat multiple indications such as rheumatoid arthritis, psoriatic arthritis and Crohn's disease, among others....
-
Orphan Drugs Among 2015's Top 10 Best-Selling Medications
Wednesday, January 18, 2017 - 11:40am | 453Orphan drugs, drugs intended to prevent, diagnose or treat rare diseases/disorders, are huge sellers for the pharmaceutical industry. NPR, citing data from EvaluatePharma, noted that seven of the 10 best-selling drugs in the United States throughout 2015 were given an orphan drug status. The main...
-
AbbVie's Humira Overhang Could Spell Trouble For Co.'s Future Upside
Monday, October 31, 2016 - 8:19am | 341Credit Suisse has lowered AbbVie Inc (NYSE: ABBV) to Neutral from Outperform, as it is “increasingly concerned about Humira's longevity given the more challenging payer environment and increasing calls for greater pricing transparency.” The downgrade follows the company’s...
-
Court Date For Litigation With Amgen And Other Expectations For AbbVie
Wednesday, October 5, 2016 - 3:19pm | 494Jefferies remains bullish on AbbVie Inc (NYSE: ABBV) as management meetings suggest the next 12 months should see significant visibility emerge for its rheumatoid arthritis drug Humira biosimilars with the earliest potential U.S. launches only being seen post-2020. The brokerage reiterated its Buy...
-
The 5 Top-Selling Drugs In The World
Tuesday, September 20, 2016 - 12:09pm | 488The 2016 election season has brought the topic of prescription drug pricing and profits into the limelight. Most patients paying for medication are acutely aware of the billions of dollars of global drug sales that the top pharmaceutical companies rake in each year. With the elections now less than...
-
Recent Deals, Pipeline Updates Setting Up AbbVie For Long-Term Growth
Thursday, September 8, 2016 - 1:55pm | 387JPMorgan said AbbVie Inc (NYSE: ABBV) should benefit from recent acquisitions as well as pipeline updates over the long term, despite downgrading the stock to Neutral from Overweight on valuation. "[G]iven the recent strength in shares, we believe AbbVie's profile is now better reflected at current...